Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
14.10
+1.24 (9.64%)
At close: May 9, 2025, 4:00 PM
14.06
-0.04 (-0.28%)
After-hours: May 9, 2025, 7:40 PM EDT
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Spyre Therapeutics stock have an average target of 50, with a low estimate of 40 and a high estimate of 65. The average target predicts an increase of 254.61% from the current stock price of 14.10.
Analyst Consensus: Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Spyre Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +219.15% | Apr 8, 2025 |
| Jones Trading | Jones Trading | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Dec 11, 2024 |
| Baird | Baird | Buy Maintains $50 → $65 | Buy | Maintains | $50 → $65 | +360.99% | Nov 13, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $50 → $65 | Strong Buy | Maintains | $50 → $65 | +360.99% | Oct 25, 2024 |
| Wedbush | Wedbush | Buy Initiates $45 | Buy | Initiates | $45 | +219.15% | Sep 4, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.51
from -3.18
EPS Next Year
-3.56
from -3.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.83 | -2.08 | -1.71 | ||
| Avg | -3.51 | -3.56 | -3.86 | ||
| Low | -4.31 | -5.06 | -5.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.